Alladapt Immunotherapeutics is identifying mechanisms to treat food allergies. Food allergy is a disease of the immune system that can be triggered by a range of common foods. For tens of millions of people, this immune response to certain foods is harmful, with potentially life-threatening consequences. As the underlying biology of food allergies grows, Alladapt is using these findings to develop a single therapeutic to support the management of a broad range of common food allergies. Alladapt’s lead drug candidate, ADP101, is being developed for the mitigation of food allergy provoked by either a single or multiple proteins from a wide range of foods. Alladapt hopes to formulate ADP101 as an oral prescription therapy that delivers highly consistent alleviation of allergies to patients.
Claim company profile to post jobs directly on this page and this website.